Search

Hutchison China MediTech Ltd ADR

Fechado

SetorSaúde

14.16 -1.73

Visão Geral

Variação de preço das ações

24h

Atual

Mín

14.24

Máximo

14.67

Indicadores-chave

By Trading Economics

Rendimento

-8.9M

-8M

Vendas

3.7M

139M

P/E

Médio do Setor

141.8

49.241

Margem de lucro

-5.724

Funcionários

1,790

EBITDA

18M

4M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+17.14% upside

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

553M

2.5B

Abertura anterior

15.89

Fecho anterior

14.16

Hutchison China MediTech Ltd ADR Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

21 de out. de 2026, 23:52 UTC

News

The Nikkei 225 Index is trading modestly lower in after-market hours, following a significant rise earlier in the day amid sector-specific movements.

21 de out. de 2026, 23:51 UTC

News

Supernus Pharmaceuticals receives seven years of orphan-drug exclusivity from the FDA for ONAPGO, a treatment for motor fluctuations in advanced Parkinson's disease.

21 de out. de 2026, 23:51 UTC

News

Regal Rexnord Corporation declared a quarterly dividend of $0.35 per share, payable on January 14, 2027, to shareholders on record as of December 31, 2026.

21 de out. de 2026, 23:51 UTC

News

A class action lawsuit has been filed against AppLovin Corporation, alleging misleading statements about its generative AI video tool's development delays.

21 de out. de 2026, 23:46 UTC

News

FMC Corporation is under investigation for securities fraud regarding undisclosed information related to its revised third-quarter guidance and significant EBITDA losses.

21 de out. de 2026, 23:46 UTC

News

Wolfe Research initiates coverage on Ross Stores Inc. with an Outperform rating and a price target of $279.

21 de out. de 2026, 23:41 UTC

News
Correlated Moves

BancFirst Corporation reported Q3 net income of $67.3 million, or $1.97 per diluted share, exceeding analyst expectations and up from $62.7 million year-over-year.

21 de out. de 2026, 23:41 UTC

News

Norfolk Southern Corporation declared a quarterly dividend of $1.35 per share, payable on November 20, 2026, continuing its 177-quarter dividend payment streak.

21 de out. de 2026, 23:31 UTC

News

Mid Penn Bancorp reported Q3 adjusted EPS of $0.88, missing the $0.89 estimate, and sales of $74.678 million, below expectations of $77.799 million.

21 de out. de 2026, 23:31 UTC

Social Media
News

Southwest Airlines reported Q3 net income of $270 million, but lowered its Q4 adjusted EPS guidance to $0.55-$0.80, below market expectations of $0.81.

21 de out. de 2026, 23:31 UTC

News
Macro News

UK Public Sector Net Borrowing for September reached £24.5 billion, exceeding forecasts, while consumer price inflation rose to 3.5%, fueling interest rate hike speculation.

21 de out. de 2026, 23:31 UTC

Social Media
Correlated Moves
News

NVIDIA launches the Vera Rubin DSX POD to expedite AI infrastructure deployment, while Needham reiterates a Buy rating with a $300 price target.

21 de out. de 2026, 23:31 UTC

News

United Airlines files an automatic mixed securities shelf for potential capital-raising efforts, amid strong third-quarter revenue growth of 17% year over year.

21 de out. de 2026, 23:26 UTC

Social Media
News

Palantir Technologies announced multiple AI deployments with clients, including L3Harris and Nvidia, despite shares trading modestly lower in after-market hours.

21 de out. de 2026, 23:26 UTC

Correlated Moves
News

Marvell Technology Inc. shares fell in after-market trading, reflecting a broader decline in the Nasdaq 100 Index amid Meta Platforms' user engagement report and fine.

21 de out. de 2026, 23:21 UTC

News

Fulton Financial Corporation reports Q3 net income of $114.1 million, exceeding expectations with total revenue of $367.3 million, shares advance in after-market trading.

21 de out. de 2026, 23:16 UTC

News

Coca-Cola Consolidated, Inc. will release its Q3 and first nine months 2026 operating results on November 4, 2026, after the market closes.

21 de out. de 2026, 23:11 UTC

News

A securities class action lawsuit has been filed against Duolingo, alleging false statements about user growth and product quality from May 2025 to February 2026.

21 de out. de 2026, 23:11 UTC

News

Robinhood Markets Inc. shares are moving lower after-market hours, reflecting a significant decline in the broader market following higher daily closes since Wednesday.

21 de out. de 2026, 23:11 UTC

News

Bybit plans to enter the U.S. market via a brokerage partnership, increasing competition for Coinbase amid a broader market decline.

21 de out. de 2026, 23:06 UTC

Correlated Moves
News

L3Harris Technologies explores proprietary AI models for mission systems, achieving a reported 95% cost reduction in early tests, according to Palantir.

21 de out. de 2026, 23:06 UTC

News

The USD/HKD exchange rate is roughly flat, having dipped to a low point before midday while remaining near the upper end of its one-month trading range.

21 de out. de 2026, 23:06 UTC

News

USD/SEK is trading lower, reflecting a decline from Tuesday's close amid reports of a decrease in the U.S. 30-year mortgage rate to 7.41%.

21 de out. de 2026, 23:06 UTC

Social Media
News

Crown Castle Inc reported third-quarter earnings of $283 million, missing analyst expectations, with site rental revenues declining to $966 million.

21 de out. de 2026, 23:06 UTC

News

Wolfe Research initiates coverage on Abercrombie & Fitch with an Outperform rating and a price target of $181.00.

21 de out. de 2026, 23:06 UTC

News

Wolfe Research initiates coverage on Deckers Outdoor Corp with a Peerperform rating, as shares closed modestly lower in after-market trading.

21 de out. de 2026, 23:06 UTC

News

Wolfe Research initiated coverage of DICK'S Sporting Goods with an Outperform rating and a price target of $181.00 amid a class action lawsuit.

21 de out. de 2026, 23:06 UTC

News

SentinelOne expands partnership with N-able to enhance cybersecurity offerings, including AI and cloud solutions for U.S. government entities.

21 de out. de 2026, 23:06 UTC

News

Bank of America faces scrutiny from a securities fraud lawsuit over anti-money laundering compliance, following a $1.2 billion fine from the Treasury.

21 de out. de 2026, 23:06 UTC

News

Boeing Co shares are trading lower in after-market hours, reflecting a decline despite the announcement of its AI platform Dataliner developed with Microsoft.

Comparação entre Pares

Variação de preço

Hutchison China MediTech Ltd ADR Previsão

Preço-alvo

By TipRanks

17.14% parte superior

Previsão para 12 meses

Média 16.833 USD  17.14%

Máximo 18.5 USD

Mínimo 14 USD

Com base em 3 analistas de Wall Street que oferecem metas de preço de 12 meses para Hutchison China MediTech Ltd ADR - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

3 ratings

2

Comprar

1

Manter

0

Vender

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat